European Archives - Page 69 of 1172 - European Medical Journal

ESWL versus FURS: Findings from PUrE RCT 1

New data from PUrE RCT 1 reveals no difference in quality-of-life between patients treated with ESWL or FURS for ≤10 mm LPSs.

Janice Walshe

Onc Now: Episode 16: Fertility, Funding, and the Future of Oncology

Janice Walshe, Consultant Medical Oncologist at St Vincent’s University Hospital in Dublin, explores access to innovation in cancer care, the challenges of fertility preservation, and the future of oncology in Ireland.

Accelerated MRI Shows High Diagnostic Accuracy for Knee Injuries

AI-accelerated knee MRI delivers sub–5-minute scans with high diagnostic accuracy, validated against arthroscopic surgical findings.

Nipple-Sparing Mastectomy Linked to Higher Patient Satisfaction

A study from Hubei Cancer Hospital has found that breast cancer patients undergoing nipple-sparing mastectomy report significantly higher satisfaction with their breast appearance and sexual well-being than those who had skin-sparing mastectomy.

Stem Cell Transplantation Outperforms Leading Multiple Sclerosis Therapies

Autologous haematopoietic stem cell transplantation outperforms alemtuzumab and ocrelizumab in relapse prevention for relapsing MS.

Beyond Glucose: Triglyceride Levels May Worsen Outcomes in Gestational Diabetes

Elevated triglycerides in well-controlled gestational diabetes linked to increased pregnancy risks, suggesting lipid monitoring may be crucial.

Rilzabrutinib Offers Hope for Patients with Refractory Urticaria

The RILECSU phase 2 clinical trial has introduced a potential new option: rilzabrutinib.

Does Certolizumab Pegol Impact QoL in Moderate-to-Severe Plaque Psoriasis?

Tune into this video to learn more about how CIMZIA® (certolizumab pegol) could impact quality of life in adult patients with…

Improving Quality of Life in Liver Cancer Treatment

Discover a new study that combined selective internal radiation therapy with nivolumab for patients with HCC.

ViiV, Roche and Gilead lead pharma patient group rankings

ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways to improve.